- Home
- RGC vs HALO Comparison
RGC vs HALO Comparison
Compare RGC & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGC | HALO |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 8.5B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RGC | HALO |
|---|---|---|
| Price | $31.18 | $71.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $76.42 |
| AVG Volume (30 Days) | 908.7K | ★ 1.6M |
| Earning Date | 10-24-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.68 |
| EPS | N/A | ★ 4.74 |
| Revenue | N/A | ★ $1,242,852,000.00 |
| Revenue This Year | N/A | $34.54 |
| Revenue Next Year | N/A | $26.28 |
| P/E Ratio | ★ N/A | $15.14 |
| Revenue Growth | N/A | ★ 31.19 |
| 52 Week Low | $0.09 | $47.50 |
| 52 Week High | $83.60 | $79.50 |
Technical Indicators
Market Signals| Indicator | RGC | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 55.10 |
| Support Level | $34.00 | $69.53 |
| Resistance Level | $69.00 | $72.33 |
| Average True Range (ATR) | 10.00 | 2.15 |
| MACD | -1.62 | -0.14 |
| Stochastic Oscillator | 20.05 | 51.36 |
Price Performance
Historical ComparisonAbout RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.